Gastrin antagonists in the treatment of gastric cancer

S. A. Watson, R. J. C. Steele

    Research output: Contribution to journalArticlepeer-review

    6 Citations (Scopus)


    The polypeptide hormone, gastrin, is known to promote both the in vitro and in vivo growth of human gastric cancer. This proliferative activity has been shown to be mediated by high affinity, membrane-associated receptors. This has led to the development of agents with the ability to antagonise gastrin receptor binding, which have been evaluated for their potential clinical value. Other anti-gastrin therapies have been investigated. As gastrin may act as an autocrine mediator of gastric tumor cell proliferation, anti-secretory agents have been evaluated, as have agents which induce the production of neutralising anti-gastrin antibodies in situ.
    Original languageEnglish
    Pages (from-to)599-604
    Number of pages6
    JournalAnti-Cancer Drugs
    Issue number6
    Publication statusPublished - 1993


    • Animals
    • Antineoplastic Agents
    • Gastrins
    • Humans
    • Receptors, Cholecystokinin
    • Stomach Neoplasms


    Dive into the research topics of 'Gastrin antagonists in the treatment of gastric cancer'. Together they form a unique fingerprint.

    Cite this